Get the Stockscreener App
2.72
5.23%
-0.15
After Hours:
2.72
Alto Neuroscience Inc stock is traded at $2.72, with a volume of 117.40K.
It is down -5.23% in the last 24 hours and up +12.86% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$2.87
Open:
$2.9
24h Volume:
117.40K
Relative Volume:
0.40
Market Cap:
$73.63M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-1.2616
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
-4.56%
1M Performance:
+12.86%
6M Performance:
-36.45%
1Y Performance:
-77.85%
1-Day Range:
$2.71
$2.90
1-Week Range:
$2.71
$3.08
52-Week Range:
$1.60
$17.55
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
2.72 | 77.16M | 0 | -49.81M | -42.93M | -2.156 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Northern Trust Corp Acquires 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
HC Wainwright Issues Pessimistic Outlook for ANRO Earnings - Defense World
Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating - TipRanks
Equities Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Wedbush Reiterates Neutral Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience Advances Precision Psychiatry Pipeline - TipRanks
Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights - marketscreener.com
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Average Target Price from Brokerages - Defense World
Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Trading Day Triumph: Alto Neuroscience Inc (ANRO) Ends at 2.17, a -0.91 Surge/Plunge - DWinneX
JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience presents new data at Society of Biological Psychiatry meeting - TipRanks
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire
Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40 - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wellington Management Group LLP Has $326,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Alto Neuroscience initiated with a Buy at H.C. Wainwright - Yahoo Finance
Alto Neuroscience (NYSE:ANRO) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Alto Neuroscience (ANRO) with Buy Recommendation - Nasdaq
Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World
ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World
What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World
William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience says its funded through 2028 - Green Market Report
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq
Alto Neuroscience Inc. (ANRO) reports earnings - Quartz
Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com
Alto Neuroscience, Inc. SEC 10-K Report - TradingView
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World
ANRO stock touches 52-week low at $3.23 amid market challenges - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR
Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN
1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):